MCID: MLR007
MIFTS: 36

Male Reproductive System Disease

Categories: Reproductive diseases

Aliases & Classifications for Male Reproductive System Disease

MalaCards integrated aliases for Male Reproductive System Disease:

Name: Male Reproductive System Disease 12 15 17
Disorder of Male Reproductive System 71
Genital Diseases, Male 43

Classifications:



External Ids:

Disease Ontology 12 DOID:48
MeSH 43 D005832
SNOMED-CT 67 64557000
ICD10 32 N50.9
UMLS 71 C0017412 C0236099

Summaries for Male Reproductive System Disease

Disease Ontology : 12 A reproductive system disease that affects male reproductive organs.

MalaCards based summary : Male Reproductive System Disease, also known as disorder of male reproductive system, is related to mouth disease and intestinal benign neoplasm, and has symptoms including nipple discharge, pain in scrotum and pain in testicle. An important gene associated with Male Reproductive System Disease is MIR199A1 (MicroRNA 199a-1), and among its related pathways/superpathways are MicroRNAs in cancer and miRNAs involved in DNA damage response. The drugs Progesterone and Hormone Antagonists have been mentioned in the context of this disorder. Affiliated tissues include prostate, bone and thyroid.

Wikipedia : 74 The male reproductive system consists of a number of sex organs that play a role in the process of human... more...

Related Diseases for Male Reproductive System Disease

Diseases related to Male Reproductive System Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 202)
# Related Disease Score Top Affiliating Genes
1 mouth disease 10.9 SERPINA3 MIR9-1 MIR31 MIR221 MIR21 MIR199A1
2 intestinal benign neoplasm 10.9 SERPINA3 MIR31 MIR21 MIR199A1 MIR17 MIR15A
3 ovary epithelial cancer 10.9 SERPINA3 MIR30A MIR21 MIR199A1 MIR17 MIR145
4 malignant ovarian surface epithelial-stromal neoplasm 10.9 SERPINA3 MIR30A MIR21 MIR199A1 MIR17 MIR145
5 cell type benign neoplasm 10.9 SERPINA3 MIR31 MIR21 MIR199A1 MIR17 MIR143
6 endocrine organ benign neoplasm 10.9 SERPINA3 MIR221 MIR21 MIR199A1 MIR17 MIR126
7 esophageal disease 10.9 MIR30A MIR21 MIR199A1 MIR17 MIR145 MIR143
8 immune system disease 10.9 SERPINA3 MIR9-1 MIR30A MIR221 MIR21 MIR199A1
9 oral cavity cancer 10.9 SERPINA3 MIR9-1 MIR31 MIR30A MIR21 MIR199A1
10 bone marrow cancer 10.9 MIR9-1 MIR30A MIR21 MIR199A1 MIR17 MIR126
11 disease of mental health 10.9 SERPINA3 MIR9-1 MIR30A MIR21 MIR199A1 MIR17
12 central nervous system disease 10.9 SERPINA3 MIR9-1 MIR30A MIR221 MIR21 MIR199A1
13 overnutrition 10.9 SERPINA3 MIR9-1 MIR222 MIR21 MIR199A1 MIR17
14 bile duct adenocarcinoma 10.9 MIR9-1 MIR31 MIR30A MIR21 MIR199A1 MIR17
15 upper respiratory tract disease 10.9 SERPINA3 MIR9-1 MIR31 MIR30A MIR21 MIR199A1
16 inherited metabolic disorder 10.9 SERPINA3 MIR9-1 MIR21 MIR199A1 MIR17 MIR126
17 cardiovascular system disease 10.9 SERPINA3 MIR21 MIR199A1 MIR17 MIR145 MIR143
18 autosomal genetic disease 10.9 SERPINA3 MIR9-1 MIR21 MIR199A1 MIR17 MIR126
19 connective tissue cancer 10.9 SERPINA3 MIR9-1 MIR31 MIR222 MIR21 MIR199A1
20 gastrointestinal system benign neoplasm 10.9 SERPINA3 MIR31 MIR21 MIR199A1 MIR17 MIR15A
21 autonomic nervous system neoplasm 10.9 SERPINA3 MIR9-1 MIR199A1 MIR17 MIR125A KDM4C
22 biliary tract disease 10.9 SERPINA3 MIR9-1 MIR31 MIR30A MIR222 MIR199A1
23 peripheral nervous system neoplasm 10.9 SERPINA3 MIR9-1 MIR199A1 MIR17 MIR125A KDM4C
24 bile duct disease 10.9 SERPINA3 MIR9-1 MIR31 MIR30A MIR222 MIR199A1
25 glucose metabolism disease 10.9 SERPINA3 MIR9-1 MIR30A MIR222 MIR21 MIR199A1
26 ovarian serous carcinoma 10.9 MIR21 MIR199A1 MIR145 MIR143 MIR141 MIR125A
27 bone inflammation disease 10.9 SERPINA3 MIR30A MIR21 MIR199A1 MIR17 MIR126
28 contractures, pterygia, and variable skeletal fusions syndrome 1a 10.9 SERPINA3 MIR9-1 MIR199A1 MIR17 KDM4C H2AC18
29 testicular disease 10.9 SERPINA3 MIR199A1 KDM4C H2AC18 EPPIN
30 gallbladder disease 10.9 SERPINA3 MIR222 MIR199A1 MIR17 MIR145 MIR143
31 diffuse large b-cell lymphoma 10.9 MIR222 MIR221 MIR21 MIR199A1 MIR17 MIR145
32 central nervous system cancer 10.9 SERPINA3 MIR9-1 MIR30A MIR222 MIR21 MIR199A1
33 lymphatic system cancer 10.9 SERPINA3 MIR17 MIR126 KDM4C H2AC18
34 pharynx cancer 10.9 SERPINA3 MIR9-1 MIR31 MIR30A MIR222 MIR21
35 retinal cancer 10.9 MIR9-1 MIR199A1 MIR17 MIR125A KDM4C H2AC18
36 oral squamous cell carcinoma 10.9 MIR9-1 MIR31 MIR221 MIR21 MIR199A1 MIR17
37 mature b-cell neoplasm 10.9 MIR9-1 MIR222 MIR199A1 MIR17 KDM4C H2AC18
38 leukocyte disease 10.9 SERPINA3 MIR9-1 MIR30A MIR222 MIR21 MIR199A1
39 cervix disease 10.9 SERPINA3 MIR9-1 MIR31 MIR30A MIR21 MIR199A1
40 ocular cancer 10.9 MIR9-1 MIR199A1 MIR17 MIR125A KDM4C H2AC18
41 cerebral arterial disease 10.9 SERPINA3 MIR145 MIR143 MIR126 MIR125A
42 autoimmune disease of musculoskeletal system 10.9 SERPINA3 MIR30A MIR221 MIR21 MIR125A H2AC18
43 muscle cancer 10.9 SERPINA3 MIR9-1 MIR199A1 MIR143 H2AC18
44 thyroid gland disease 10.9 MIR9-1 MIR30A MIR222 MIR221 MIR21 MIR199A1
45 renal cell carcinoma, nonpapillary 10.9 MIR9-1 MIR30A MIR221 MIR21 MIR199A1 MIR17
46 aortic valve disease 2 10.9 SERPINA3 MIR21 MIR199A1 MIR17 MIR126
47 skin disease 10.9 SERPINA3 MIR31 MIR21 MIR199A1 MIR17 MIR126
48 nasopharyngeal disease 10.9 MIR9-1 MIR31 MIR30A MIR21 MIR199A1 MIR17
49 connective tissue disease 10.9 SERPINA3 MIR9-1 MIR31 MIR30A MIR222 MIR221
50 rectum cancer 10.9 MIR31 MIR21 MIR17 MIR145 MIR143 MIR125A

Graphical network of the top 20 diseases related to Male Reproductive System Disease:



Diseases related to Male Reproductive System Disease

Symptoms & Phenotypes for Male Reproductive System Disease

UMLS symptoms related to Male Reproductive System Disease:


nipple discharge, pain in scrotum, pain in testicle, perineal pain male

Drugs & Therapeutics for Male Reproductive System Disease

Drugs for Male Reproductive System Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 65)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
2 Hormone Antagonists Phase 4
3 Hormones Phase 4
4 Progestins Phase 4
5
Tadalafil Approved, Investigational Phase 3 171596-29-5 110635
6 Vasodilator Agents Phase 3
7 Phosphodiesterase Inhibitors Phase 3
8 Phosphodiesterase 5 Inhibitors Phase 3
9
Finasteride Approved Phase 2 98319-26-7 57363
10
Methyltestosterone Approved Phase 2 58-18-4 6010
11
Testosterone Approved, Experimental, Investigational Phase 2 58-22-0, 481-30-1 6013 10204
12
Testosterone undecanoate Approved, Investigational Phase 2 5949-44-0
13
Testosterone enanthate Approved Phase 2 315-37-7 9416
14 Onapristone Investigational Phase 1, Phase 2 96346-61-1
15 Bombesin Investigational Phase 1, Phase 2 31362-50-2
16 Fertility Agents Phase 1, Phase 2
17 Imatinib Mesylate Phase 2 220127-57-1 123596
18 Protein Kinase Inhibitors Phase 2
19 5-alpha Reductase Inhibitors Phase 2
20 Anabolic Agents Phase 2
21 Steroid Synthesis Inhibitors Phase 2
22 Antineoplastic Agents, Hormonal Phase 2
23 Testosterone 17 beta-cypionate Phase 2
24 Androgens Phase 2
25 Renal Agents Phase 2
26 Anti-Bacterial Agents Phase 2
27 Anti-Infective Agents, Urinary Phase 2
28 Amdinocillin Pivoxil Phase 2
29 Anti-Infective Agents Phase 2
30 Neurotransmitter Agents Phase 1, Phase 2
31 Gastrointestinal Agents Phase 1, Phase 2
32 Radiopharmaceuticals Phase 1, Phase 2
33 Gastrins Phase 1, Phase 2
34 gastrin-releasing peptide Phase 1, Phase 2
35 Epothilones Phase 2
36 Antimitotic Agents Phase 2
37
Niraparib Approved, Investigational Phase 1 1038915-60-4 24958200
38
Tacrolimus Approved, Investigational Phase 1 104987-11-3 445643 439492 6473866
39 Vaccines Phase 1
40 Cola Phase 1
41 Poly(ADP-ribose) Polymerase Inhibitors Phase 1
42 Immunologic Factors Phase 1
43 Antibodies, Monoclonal Phase 1
44 Immunoglobulins Phase 1
45 Antibodies Phase 1
46 Immunosuppressive Agents Phase 1
47 Calcineurin Inhibitors Phase 1
48
Prednisolone Approved, Vet_approved 50-24-8 5755
49
Methylprednisolone hemisuccinate Approved 2921-57-5
50
Methylprednisolone Approved, Vet_approved 83-43-2 6741

Interventional clinical trials:

(show all 22)
# Name Status NCT ID Phase Drugs
1 Oral Dydrogesterone Versus Micronized Vaginal Progesterone for Luteal Phase Support in In Vitro Fertilisation (IVF)/ IntraCytoplasmic Sperm Injection (ICSI): Pharmacokinetics and the Impact on the Endometrium, the Microbiota of the Genital Tract and the Peripheral Immunology. Double Blind Crossover Study. Recruiting NCT03677336 Phase 4 Dydrogesterone Oral Tablet;Micronized progesterone;Placebo Dydrogesterone oral tablet;Placebo Micronized progesterone
2 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multinational Study to Evaluate the Efficacy and Safety of Daily Tadalafil for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia Completed NCT00827242 Phase 3 Placebo;tadalafil
3 Randomized Trial of Male Circumcision for HIV Prevention, Rakai, Uganda Completed NCT00425984 Phase 3
4 A Phase 1-2 Study of Onapristone in Patients With Advanced Castration-resistant Prostate Cancer Unknown status NCT02049190 Phase 1, Phase 2 onapristone;abiraterone
5 An Open-label, Multicenter, Phase II Study to Evaluate the Ability of Glivec® (Imatinib, Formerly Known as STI571) to Produce a Biochemical Response in Patients With Rising PSA Following Radical Prostatectomy Completed NCT01316458 Phase 2 STI571 (Glivec®)
6 Higher-Than-Replacement Testosterone Plus Finasteride Treatment After SCI Recruiting NCT02248701 Phase 2 testosterone enanthate, finasteride;placebo
7 Mecillinam for Treatment of Genital Chlamydia Infection in Asymptomatic Men Terminated NCT02083276 Phase 2 Pivmecillinamhydrochlorid
8 An Open-label, Multi Center PET/CT Study for Investigation of Safety and Diagnostic Performance of the 68Ga Labeled PET Tracer [68Ga]RM2 in Patients With Primary Prostate Cancer Terminated NCT02483884 Phase 1, Phase 2 [68Ga]RM2
9 A Phase II Study of Ixabepilone Prior to Surgery for High-risk Localized Prostate Cancer Terminated NCT00672009 Phase 2 Ixabepilone
10 A Phase 1/2 Open-Label Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral EPI-506 in Patients With Metastatic Castration-Resistant Prostate Cancer Terminated NCT02606123 Phase 1, Phase 2 EPI-506
11 A Phase I Investigation of the Safety, Tolerability and Immunogenicity of V934/V935 hTERT Vaccination in Cancer Patients With Selected Solid Tumors Completed NCT00753415 Phase 1
12 A Phase I Study of MK-4827 in Patients With Advanced Solid Tumors or Hematologic Malignancies Completed NCT00749502 Phase 1 MK-4827
13 Vascularized Composite Allotransplantation (VCA) for Devastating Penile and Concomitant Genital Trauma Recruiting NCT03240822 Phase 1 Tacrolimus
14 An Open-Label Phase 1b QT/QTc Study of JNJ-56021927 (ARN-509) in Subjects With Castration-Resistant Prostate Cancer Active, not recruiting NCT02578797 Phase 1 Apalutamide
15 Use of the LANDA Embryo Freezing Technique to Validate Frozen Embryo Transfer Success Rates Unknown status NCT01271400
16 An Open Label Study of Abiraterone Acetate in Subjects With Metastatic Castration-Resistant Prostate Cancer Who Have Progressed After Taxane-Based Chemotherapy Approved for marketing NCT01217697 Abiraterone Acetate;Prednisone\Prednisolone
17 Eeva Continued Access Study. Completed NCT01617993
18 Randomized, Evaluator-blind, Controlled Trial to Evaluate the Efficacy and Safety of Prostatic Arterial Embolization Versus a Sham Procedure for Benign Prostatic Hyperplasia With Severe LUTS Not Adequately Controlled With Alpha-blockers Completed NCT02074644
19 Performance of Nucleic Acid Amplification Tests for the Detection of Neisseria Gonorrhoeae and Chlamydia Trachomatis in Extragenital Sites Completed NCT02870101
20 Human Sperm Zona Acceptor: Environmental Effects Completed NCT00012480
21 Prostate Artery Embolization Safety and Efficacy: A Pilot Study Recruiting NCT02592473
22 Culturally Adapted Cognitive Behavioral Stress and Self-Management (C-CBSM) Intervention for Prostate Cancer Recruiting NCT03344757

Search NIH Clinical Center for Male Reproductive System Disease

Cochrane evidence based reviews: genital diseases, male

Genetic Tests for Male Reproductive System Disease

Anatomical Context for Male Reproductive System Disease

MalaCards organs/tissues related to Male Reproductive System Disease:

40
Prostate, Bone, Thyroid, Breast, Heart, Colon, Ovary

Publications for Male Reproductive System Disease

Variations for Male Reproductive System Disease

Expression for Male Reproductive System Disease

Search GEO for disease gene expression data for Male Reproductive System Disease.

Pathways for Male Reproductive System Disease

Pathways related to Male Reproductive System Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.96 MIR9-1 MIR31 MIR30A MIR222 MIR221 MIR21
2 11.03 MIR222 MIR221 MIR145
3 10.84 MIR9-1 MIR222 MIR221 MIR199A1
4 10.37 MIR199A1 MIR145

GO Terms for Male Reproductive System Disease

Cellular components related to Male Reproductive System Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.53 SERPINA3 MIR31 MIR30A MIR222 MIR221 MIR21

Biological processes related to Male Reproductive System Disease according to GeneCards Suite gene sharing:

(show all 36)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 10.04 MIR30A MIR21 MIR182 MIR125A KDM4C
2 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.93 MIR222 MIR221 MIR21 MIR126
3 positive regulation of protein kinase B signaling GO:0051897 9.91 MIR222 MIR221 MIR21 MIR199A1 MIR143 MIR126
4 positive regulation of angiogenesis GO:0045766 9.88 MIR31 MIR30A MIR21 MIR199A1 MIR143 MIR126
5 negative regulation of inflammatory response GO:0050728 9.85 MIR31 MIR222 MIR221 MIR15A MIR141 MIR126
6 positive regulation of G1/S transition of mitotic cell cycle GO:1900087 9.79 MIR30A MIR222 MIR221
7 positive regulation of epithelial to mesenchymal transition GO:0010718 9.79 MIR222 MIR221 MIR21
8 negative regulation of cardiac muscle cell apoptotic process GO:0010667 9.77 MIR21 MIR199A1 MIR145
9 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.76 MIR222 MIR221 MIR21 MIR17
10 positive regulation of sprouting angiogenesis GO:1903672 9.73 MIR31 MIR126 MIR125A
11 positive regulation of vascular associated smooth muscle cell migration GO:1904754 9.72 MIR221 MIR21 MIR143
12 positive regulation of blood vessel endothelial cell migration GO:0043536 9.72 MIR31 MIR30A MIR221 MIR143 MIR126
13 negative regulation of angiogenesis GO:0016525 9.7 MIR222 MIR21 MIR15A MIR145 MIR143 MIR125A
14 negative regulation of cardiac muscle hypertrophy GO:0010614 9.67 MIR21 MIR145
15 regulation of smooth muscle contraction GO:0006940 9.67 MIR145 MIR143
16 negative regulation of low-density lipoprotein particle clearance GO:0010989 9.66 MIR199A1 MIR17
17 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.66 MIR199A1 MIR17
18 positive regulation of axon regeneration GO:0048680 9.65 MIR222 MIR221
19 positive regulation of metalloendopeptidase activity GO:1904685 9.65 MIR21 MIR17
20 negative regulation by host of viral genome replication GO:0044828 9.65 MIR222 MIR221
21 negative regulation of vascular associated smooth muscle cell migration GO:1904753 9.65 MIR21 MIR182 MIR15A
22 miRNA mediated inhibition of translation GO:0035278 9.65 MIR9-1 MIR31 MIR30A MIR222 MIR221 MIR21
23 angiotensin-activated signaling pathway GO:0038166 9.64 MIR145 MIR143
24 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.63 MIR21 MIR17
25 aorta smooth muscle tissue morphogenesis GO:0060414 9.62 MIR145 MIR143
26 regulation of phenotypic switching GO:1900239 9.61 MIR145 MIR143
27 negative regulation of cell adhesion molecule production GO:0060354 9.6 MIR222 MIR221
28 positive regulation of pulmonary blood vessel remodeling GO:1905111 9.58 MIR17 MIR143
29 negative regulation of TRAIL-activated apoptotic signaling pathway GO:1903122 9.58 MIR222 MIR221
30 positive regulation of Schwann cell migration GO:1900149 9.57 MIR222 MIR221
31 negative regulation of leukocyte adhesion to vascular endothelial cell GO:1904995 9.56 MIR31 MIR222 MIR221 MIR141
32 negative regulation of vascular smooth muscle cell dedifferentiation GO:1905175 9.54 MIR182 MIR145
33 positive regulation of Schwann cell proliferation involved in axon regeneration GO:1905046 9.52 MIR222 MIR221
34 negative regulation of hematopoietic stem cell proliferation GO:1902034 9.51 MIR222 MIR221
35 gene silencing by miRNA GO:0035195 9.5 MIR9-1 MIR31 MIR30A MIR222 MIR221 MIR21
36 establishment or maintenance of cell type involved in phenotypic switching GO:0044663 9.49 MIR145 MIR143

Molecular functions related to Male Reproductive System Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.5 MIR9-1 MIR31 MIR30A MIR222 MIR221 MIR21
2 RNA polymerase II complex binding GO:0000993 9.13 MIR145 MIR126 MIR125A

Sources for Male Reproductive System Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....